Novartis Pharmaceuticals Corporation v. Adesanya, 613 B.R. 808

Background

Novartis sued former employee Afoluso (and her husband Adenekan) in federal court for fraud, breach of a relocation agreement, breach of the Annual Incentive Plan (AIP), breach of duty of loyalty, and related counterclaims; the District Court found Afoluso liable, dismissed her claims, and imposed damages and sanctions (including substantial attorneys’ fees assessed against Afoluso and a smaller sanctions award against Adenekan).
Key factual findings by the District Court: Afoluso misrepresented her employment history/supervisors and salary, failed to disclose outside consulting and ownership interests (LaRon/Global/Biomedical/Auxilium/Astellas), did not relocate as promised, and billed/worked for competitors while employed by Novartis.
Novartis filed an adversary proceeding in bankruptcy seeking to except the District Court judgment (and certain ancillary awards/sanctions) from discharge under 11 U.S.C. § 523(a)(2)(A) (false representations/false pretenses/actual fraud) and related provisions; Novartis relied heavily on collateral estoppel from the District Court findings.
Debtors (Afoluso and Adenekan) opposed summary judgment, disputing that the prior findings establish the state of mind required for nondischargeability and arguing that some challenged statements fall within § 523(a)(2)(B) (statements respecting a debtor’s financial condition) or otherwise do not support nondischargeability.
The bankruptcy court applied collateral estoppel to portions of the District Court opinions, granting Novartis partial summary judgment on claims where the prior findings satisfied elements of § 523(a)(2)(A), but denied or reserved ruling on other portions (notably sanctions and ancillary awards) where material issues—especially the debtor’s intent, whether the debt derived from statements "respecting financial condition," or whether certain damages are traceable to fraud—remained.

Issues

Issue	Plaintiff's Argument (Novartis)	Defendant's Argument (Debtors)	Held
1) Do the District Court findings have preclusive effect to establish elements of §523(a)(2)(A)?	District Court findings satisfy the falsity, reliance, and damages elements; collateral estoppel bars relitigation and supports nondischargeability for portions of the judgment.	Prior findings do not resolve the Debtors’ subjective intent on elements requiring state of mind; some findings are not specific enough to establish all §523(a)(2)(A) elements.	Court applied collateral estoppel to many District Court findings and granted partial summary judgment to Novartis where the findings plainly satisfied §523(a)(2)(A), but reserved other issues for trial when intent or causal traceability remained disputed.
2) Do the omissions/misrepresentations about employment, outside work, and AIP eligibility fall within §523(a)(2)(A) or instead require §523(a)(2)(B) (financial-condition statements)?	Omissions and implied misrepresentations about employment status and eligibility induced Novartis to hire/pay Afoluso and fall within §523(a)(2)(A).	Some contested statements concern the debtor’s financial condition or compensation and therefore would be analyzed under §523(a)(2)(B), which has distinct requirements.	Court held many omissions/implied misrepresentations (conflicts, outside employment, failure to relocate) could be treated under §523(a)(2)(A); but it noted limits where the statement is properly a "statement respecting financial condition," reserving those aspects for further analysis.
3) Is the sanctions award against Adenekan nondischargeable under §523(a)(2)(A)?	Novartis argued sanctions stemmed from discovery misconduct related to fraudulent conduct and should be nondischargeable.	Adenekan did not obtain money/property as a result of the misconduct; sanctions for discovery misconduct are not the kind of debt excepted by §523(a)(2)(A).	Court concluded there is no genuine dispute that Adenekan did not receive money/property from the misconduct and denied nondischargeability as to that sanctions award.
4) Are ancillary/attorney-fee awards and sanctions against Afoluso nondischargeable as arising from fraudulent conduct?	Fees and ancillary damages are inseparable from the fraudulent scheme and thus nondischargeable under Cohen and related precedent.	Some awards may not be directly traceable to fraud or may rest on legal theories (contract, punitive statutory treble) requiring separate analysis; debtor’s intent and traceability remain disputed.	Court held portions of the award traceable to the District Court’s fraud findings may be nondischargeable and granted partial relief to Novartis on those portions, but reserved determination of other ancillary amounts (including aspects of the sanctions award) for trial.

Key Cases Cited

Cohen v. De La Cruz, 523 U.S. 213 (1998) (§523(a)(2)(A) covers all liability arising from fraud, including ancillary damages)
Husky Int’l Elecs., Inc. v. Ritz, 136 S. Ct. 1581 (2016) (definition and scope of "false pretenses" and intent under §523(a)(2)(A))
Lamar, Archer & Cofrin, LLP v. Appling, 138 S. Ct. 1752 (2018) (interpretation of "statement respecting the debtor’s financial condition" under §523(a)(2)(B))
Grogan v. Garner, 498 U.S. 279 (1991) (burden of proof in nondischargeability proceedings)
Murphy v. Snyder (In re Snyder), 939 F.3d 92 (3d Cir. 2019) (collateral estoppel and nondischargeability principles in the Third Circuit)
Coluccio v. Sevastakis (In re Sevastakis), 591 B.R. 197 (Bankr. D.N.J. 2018) (application of collateral estoppel to prior federal-court fraud findings)
In re Glunk, 343 B.R. 754 (Bankr. W.D. Pa. 2006) (use of prior findings and admissions in nondischargeability summary-judgment context)